Product Center
Welcome to the centralized signing of the project
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-05-24
- Views:
(Summary description)In Taizhou in June, the fragrance of gardenias, the rain moistens everything, and it is full of splendor. It is a good time for China Medical City, full of innovation and vitality, to increase its new
Welcome to the centralized signing of the project
(Summary description)In Taizhou in June, the fragrance of gardenias, the rain moistens everything, and it is full of splendor. It is a good time for China Medical City, full of innovation and vitality, to increase its new
- Categories:Company news
- Author:
- Origin:
- Time of issue:2022-05-24 16:06
- Views:
Information
In Taizhou in June, the fragrance of gardenias, the rain moistens everything, and it is full of splendor. It is a good time for China Medical City, full of innovation and vitality, to increase its new advantages in innovation and development, and to start a second entrepreneurship! Under this wave of entrepreneurship in full swing, the vigorous Ab&B Bio-Tech CO.,LTD.JS ushered in the milestone moment of the signing of projects.
The highlights of the projects signed this time are frequent and eye-catching. The project plans to add an additional investment of 1 billion yuan, focusing on promoting the preclinical research, registration application and clinical application of 5 innovative vaccine projects including the new coronavirus genetic engineering vaccine, 23-valent pneumococcal polysaccharide vaccine, pneumonia conjugate vaccine, and recombinant shingles. test. At the same time, it has completed the A round of financing of 300 million yuan with Shenzhen Gaotejia Investment Group, Shengshi Jintai, Guohai Venture Capital, Zhuzhou International Investment, Yida Capital and other investment institutions to help escort the orderly progress of the project.
Zhang Xiaobing, member of the Standing Committee of Taizhou Municipal Party Committee and Secretary of the Party Working Committee of Taizhou Pharmaceutical High-tech Zone, proposed in his speech that all relevant departments of China Medical City will focus on creating a professional business with "more linking services", "more accurate policy support" and "faster review and approval". As an environmental brand, we will do our best to provide more convenient, high-quality and thoughtful services for the Ab&B Bio-Tech CO.,LTD.JS Project, and make every effort to promote the early start, early production and early effect of the project.
The project signing representative, Changjiang Lu Bin, Deputy Institute of the Pasteur Institute, Shanghai, Chinese Academy of Sciences, said about the cooperation: The cooperation between the two parties on the new coronavirus pneumonia (COVID-19) genetically engineered vaccine is to give full play to the vaccine innovation of the Pasteur Institute in Shanghai. The advantages and the vaccine industrialization capability of Ab&B Bio-Tech CO.,LTD.JS are based on the current and long-term strategic cooperation. We look forward to using this cooperation as a starting point to combine production, academia and research to accelerate the development, production and launch of more innovative vaccines.
Wang Shuguang, the executive partner of Shenzhen Gaotejia Investment Management Group (Shanghai), on behalf of investment institutions, has a lot of feelings: We are fortunate to invest in Ab&B Bio-Tech CO.,LTD.JS in 2018 and become Ab&B Bio-Tech CO.,LTD.JS's comrades-in-arms, partners and fans, standing together through thick and thin. Watching Ab&B Bio-Tech CO.,LTD.JS develop from a construction site to a modern vaccine factory, from an obscure early R&D company to a rising star in the vaccine industry, I feel gratified and fulfilled. The development history of Ab&B Bio-Tech CO.,LTD.JS is like a microcosm of the development of China Medical City. We are full of confidence and expectations for China Medical City. We look forward to establishing more in-depth and long-term cooperation with China Medical City, serving more companies like Ab&B Bio-Tech CO.,LTD.JS Bio, and serving China's future pharmaceutical industry to make our contribution.
An Youcai, Chairman/General Manager of Jiangsu Ab&B Bio-Tech CO.,LTD.JS, briefly described the four-year rapid development of Ab&B Bio-Tech CO.,LTD.JS in his speech at the signing ceremony, and gave strong support, care and concern to Ab&B Bio-Tech CO.,LTD.JS on the way forward. , The leaders, experts and cooperative units at all levels who pay attention, guide and serve express sincere thanks! At the same time, he also said that in the new journey of the second entrepreneurship of China Medical City, we will only fight for the day and night, work hard, and promote more new projects to take root, bear fruit, be brave participants and leaders, and work hard to achieve a win-win situation!
The achievements in the past are worth remembering, and we should run hard in the future. Be encouraged in time, time waits for no one. When we are born at the right time, we have fire in our hearts and light in our eyes, let’s run, Ab&B Bio-Tech CO.,LTD.JS creatures!
Scan the QR code to read on your phone
Relevant information
-
Influenza virus subunit vaccine (adjuvant) IND application approvedRecently, Ab&B Bio-Tech Co.,Ltd（Ab&B Bio）and its subsidiary Yither biotech (Shanghai) Co., Ltd (Yither Bio) jointly applied for a Class I new drug "Influenza Virus Subunit Vaccine (Adjuvant)" IND application, which has been approved by the Drug Evaluation Center (CDE) of the China National Medical Products Administration. The approval of this vaccine marks the completion of the full coverage of the company's subunit influenza vaccine product pipeline for trivalent and quadrivalent influenza virus subunit vaccines, providing the most accurate selection for different age groups and different demand groups. - The application for the marketing of trivalent influenza virus subunit vaccine has been accepted! 10-08
- Breaking through bottleneck technology, significant progress has been made in the research and development of new adjuvants 08-26
- Obtained recognition as one of the first offshore innovation centers for enterprises in Taizhou 08-14
- Recombinant herpes zoster vaccine (CHO cells) IND application approved 08-13
Have a project？Get a touch!
Caring for life, protecting health, and making global technological innovation vaccines are the mission of Ab&B Bio
Contact
E-mail:info@abbbio.com.cn
Add:No. 32, Xinglin Road, Medical High-tech Zone, Taizhou City
Quick view
Follow us
